Literature DB >> 31700162

Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion.

Seung-Mo Hong1,2, DongJun Jung1,3, Ashley Kiemen4, Matthias M Gaida5,6, Tadashi Yoshizawa1, Alicia M Braxton1, Michaël Noë7, Gemma Lionheart1, Kiyoko Oshima1, Elizabeth D Thompson1,7, Richard Burkhart8, Pei-Hsun Wu4, Denis Wirtz1,4, Ralph H Hruban9,10, Laura D Wood11,12.   

Abstract

Venous invasion is three times more common in pancreatic cancer than it is in other major cancers of the gastrointestinal tract, and venous invasion may explain why pancreatic cancer is so deadly. To characterize the patterns of venous invasion in pancreatic cancer, 52 thick slabs (up to 5 mm) of tissue were harvested from 52 surgically resected human ductal adenocarcinomas, cleared with a modified iDISCO method, and labeled with fluorescent-conjugated antibodies to cytokeratin 19, desmin, CD31, p53 and/or e-cadherin. Labeled three-dimensional (3D) pancreas cancer tissues were visualized with confocal laser scanning or light sheet microscopy. Multiple foci of venous and even arterial invasion were visualized. Venous invasion was detected more often in 3D (88%, 30/34 cases) than in conventional 2D slide evaluation (75%, 25/34 cases, P < 0.001). 3D visualization revealed pancreatic cancer cells crossing the walls of veins at multiple points, often at points where preexisting capillary structures bridge the blood vessels. The neoplastic cells often retained a ductal morphology (cohesive cells forming tubes) as they progressed from a stromal to intravenous location. Although immunolabeling with antibodies to e-cadherin revealed focal loss of expression at the leading edges of the cancers, the neoplastic cells within veins expressed e-cadherin and formed well-oriented glands. We conclude that venous invasion is almost universal in pancreatic cancer, suggesting that even surgically resectable PDAC has access to the venous spaces and thus the ability to disseminate widely. Furthermore, we observe that sustained epithelial-mesenchymal transition is not required for venous invasion in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31700162     DOI: 10.1038/s41379-019-0409-3

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   8.209


  2 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion.

Authors:  Masaya Suenaga; Tsutomu Fujii; Mitsuro Kanda; Hideki Takami; Norio Okumura; Yoshikuni Inokawa; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Hiroyuki Sugimoto; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Hepatogastroenterology       Date:  2014-09
  2 in total
  12 in total

1.  Cancerization of ducts in hilar cholangiocarcinoma.

Authors:  Jae W Lee; Yang Zhang; Tadashi Yoshizawa; Pedram Argani; Laura D Wood; Kiyoko Oshima
Journal:  Virchows Arch       Date:  2022-05-09       Impact factor: 4.535

2.  THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.

Authors:  Shirsa Udgata; Naomi Takenaka; William R Bamlet; Ann L Oberg; Stephanie S Yee; Erica L Carpenter; Daniel Herman; Jungsun Kim; Gloria M Petersen; Kenneth S Zaret
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-16

Review 3.  Pancreas Optical Clearing and 3-D Microscopy in Health and Diabetes.

Authors:  Martha Campbell-Thompson; Shiue-Cheng Tang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 6.055

Review 4.  The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.

Authors:  Elizabeth D Thompson; Nicholas J Roberts; Laura D Wood; James R Eshleman; Michael G Goggins; Scott E Kern; Alison P Klein; Ralph H Hruban
Journal:  Mod Pathol       Date:  2020-07-23       Impact factor: 7.842

5.  Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers.

Authors:  Junyoung Shin; Laura D Wood; Ralph H Hruban; Seung-Mo Hong
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

Review 6.  Mesoscopic Optical Imaging of the Pancreas-Revisiting Pancreatic Anatomy and Pathophysiology.

Authors:  Tomas Alanentalo; Max Hahn; Stefanie M A Willekens; Ulf Ahlgren
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-04       Impact factor: 5.555

Review 7.  Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management.

Authors:  Daniel Schreyer; John P Neoptolemos; Simon T Barry; Peter Bailey
Journal:  Front Cell Dev Biol       Date:  2022-01-13

Review 8.  Tissue clearing to examine tumour complexity in three dimensions.

Authors:  Jorge Almagro; Hendrik A Messal; May Zaw Thin; Jacco van Rheenen; Axel Behrens
Journal:  Nat Rev Cancer       Date:  2021-07-30       Impact factor: 60.716

Review 9.  Malignant epithelial/exocrine tumors of the pancreas.

Authors:  Claudio Luchini; Federica Grillo; Matteo Fassan; Alessandro Vanoli; Paola Capelli; Gaetano Paolino; Giuseppe Ingravallo; Giuseppina Renzulli; Claudio Doglioni; Alessandro D'Amuri; Paola Mattiolo; Sara Pecori; Paola Parente; Ada M Florena; Giuseppe Zamboni; Aldo Scarpa
Journal:  Pathologica       Date:  2020-09

10.  3D imaging of human organs with micrometer resolution - applied to the endocrine pancreas.

Authors:  Max Hahn; Christoffer Nord; Maria Eriksson; Federico Morini; Tomas Alanentalo; Olle Korsgren; Ulf Ahlgren
Journal:  Commun Biol       Date:  2021-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.